SG Americas Securities LLC Purchases New Shares in Vera Therapeutics, Inc. (NASDAQ:VERA)

SG Americas Securities LLC purchased a new stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 7,709 shares of the company’s stock, valued at approximately $119,000.

Other hedge funds also recently bought and sold shares of the company. UBS Group AG purchased a new stake in Vera Therapeutics during the first quarter valued at $47,000. Ameritas Investment Partners Inc. raised its stake in shares of Vera Therapeutics by 163.1% in the second quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company’s stock valued at $45,000 after acquiring an additional 1,731 shares during the period. Royal Bank of Canada raised its stake in shares of Vera Therapeutics by 94.8% in the second quarter. Royal Bank of Canada now owns 3,339 shares of the company’s stock valued at $54,000 after acquiring an additional 1,625 shares during the period. Amalgamated Bank raised its stake in shares of Vera Therapeutics by 26.0% in the third quarter. Amalgamated Bank now owns 4,189 shares of the company’s stock valued at $57,000 after acquiring an additional 864 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in shares of Vera Therapeutics by 810.4% in the first quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company’s stock valued at $38,000 after acquiring an additional 4,303 shares during the period. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 1.3 %

Shares of Vera Therapeutics stock opened at $39.48 on Friday. The company has a debt-to-equity ratio of 0.49, a current ratio of 7.71 and a quick ratio of 7.71. Vera Therapeutics, Inc. has a 1 year low of $6.07 and a 1 year high of $50.78. The firm’s 50-day moving average is $43.76 and its two-hundred day moving average is $25.75. The stock has a market cap of $2.15 billion, a price-to-earnings ratio of -17.24 and a beta of 1.05.

Vera Therapeutics (NASDAQ:VERA) last issued its earnings results on Wednesday, March 20th. The company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.05). As a group, research analysts expect that Vera Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Vera Therapeutics news, Director Maha Katabi bought 161,290 shares of the company’s stock in a transaction on Tuesday, January 30th. The shares were bought at an average cost of $31.00 per share, for a total transaction of $4,999,990.00. Following the acquisition, the director now directly owns 3,628,446 shares in the company, valued at $112,481,826. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO Sean Grant sold 99,828 shares of Vera Therapeutics stock in a transaction that occurred on Wednesday, April 3rd. The shares were sold at an average price of $39.61, for a total value of $3,954,187.08. Following the transaction, the chief financial officer now owns 66,337 shares of the company’s stock, valued at approximately $2,627,608.57. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Maha Katabi acquired 161,290 shares of the business’s stock in a transaction dated Tuesday, January 30th. The stock was purchased at an average cost of $31.00 per share, for a total transaction of $4,999,990.00. Following the transaction, the director now owns 3,628,446 shares in the company, valued at $112,481,826. The disclosure for this purchase can be found here. Insiders have sold a total of 526,551 shares of company stock worth $21,533,345 in the last three months. Corporate insiders own 21.70% of the company’s stock.

Analysts Set New Price Targets

VERA has been the topic of several recent analyst reports. Raymond James raised shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their target price for the company from $29.00 to $37.00 in a research note on Friday, January 26th. Oppenheimer initiated coverage on shares of Vera Therapeutics in a research note on Thursday, January 25th. They issued an “outperform” rating and a $26.00 target price on the stock. Wedbush increased their target price on shares of Vera Therapeutics from $21.00 to $34.00 and gave the company a “neutral” rating in a research note on Thursday, March 21st. Guggenheim restated a “buy” rating and issued a $56.00 price target on shares of Vera Therapeutics in a report on Friday, April 5th. Finally, Cantor Fitzgerald started coverage on shares of Vera Therapeutics in a report on Monday, January 8th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Vera Therapeutics currently has an average rating of “Buy” and an average price target of $32.29.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.